RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
Public ClinicalTrials.gov record NCT00410124. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor
Study identification
- NCT ID
- NCT00410124
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 416 participants
Conditions and interventions
Conditions
Interventions
- RAD001 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Jan 31, 2008
- Completion
- Sep 30, 2011
- Last update posted
- Jan 14, 2013
2006 – 2011
United States locations
- U.S. sites
- 31
- U.S. states
- 18
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Fayetteville | Arkansas | 72703 | — |
| Novartis Investigative Site | Duarte | California | 91010-3000 | — |
| Novartis Investigative Site | Sacramento | California | 95817 | — |
| Novartis Investigative Site | San Francisco | California | 94115 | — |
| Novartis Investigative Site | Santa Monica | California | 90404 | — |
| Novartis Investigative Site | Ocoee | Florida | *see dep* | — |
| Novartis Investigative Site | Orlando | Florida | 32806 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46202 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46227 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40202 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21201 | — |
| Novartis Investigative Site | Detroit | Michigan | 48201 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55455 | — |
| Novartis Investigative Site | Columbia | Missouri | 65201 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89135 | — |
| Novartis Investigative Site | Buffalo | New York | 14263 | — |
| Novartis Investigative Site | New York | New York | 10021 | — |
| Novartis Investigative Site | Chapel Hill | North Carolina | 27599 | — |
| Novartis Investigative Site | Durham | North Carolina | 27710 | — |
| Novartis Investigative Site | Raleigh | North Carolina | 27609 | — |
| Novartis Investigative Site | Canton | Ohio | 44718 | — |
| Novartis Investigative Site | Portland | Oregon | 97210 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15232 | — |
| Novartis Investigative Site | Bedford | Texas | 76022 | — |
| Novartis Investigative Site | Dallas | Texas | 75246 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229 | — |
| Novartis Investigative Site | Tyler | Texas | 75702 | — |
| Novartis Investigative Site | Seattle | Washington | 98109-1023 | — |
| Novartis Investigative Site | Spokane | Washington | 99202 | — |
| Novartis Investigative Site | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00410124, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 14, 2013 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00410124 live on ClinicalTrials.gov.